Benchmarking Structural Variant Detection in Whole-Exome Sequencing of 67 Multiple Myeloma Cell Lines

Background. Although the majority of structural variant (SV) workflows have been derived based on whole genome sequencing (WGS) data, they continue to be applied to whole exome sequence (WES) data for which many studies have evaluated their performance in cancer. An equally important consideration that has not been well studied is the impact of cancer context specific features among WGS-derived SV callers applied to WES data. Similar to personalized medicine, not all SV callers are alike and optimal for use with all cancer types and sequence data types. In addition to sequencing related data f

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.